Authors: Babine, Robert E; Villafranca, J Ernest; Gold, Bruce G

Source: Expert Opinion on Therapeutic Patents, Volume 15, Number 5, 1 May 2005 , pp. 555-573(19)

Publisher: Informa Healthcare

Abstract:

Immunophilins are a family of binding proteins that are highly conserved in nature and mediate the actions of immunosuppressant drugs. The FK-506-binding protein (FKBP) subclass of immunophilin bind FK-506 and rapamycin and are of particular interest due to their potent neurotrophic activity. Here, the patent literature covering the structures of novel non-immuno-suppressant derivatives of FK-506 and rapamycin, and their claims pertaining to their potential use for the treatment of neurological disorders, are reviewed.

Keywords: FK-506; FKBP; FKBP-12; FKBP-52; immunophilin; neurodegenerative disease; tacrolimus; rapamycin

Document Type: Review article

DOI: http://dx.doi.org/10.1517/13543776.15.5.555

Publication date: 2005-05-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Babine, Robert E ;  Villafranca, J Ernest ;  Gold, Bruce G

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers